集友股份(603429.SH):控股股東及董監高提前終止減持計劃 合計減持2164.39萬股
格隆匯12月28日丨集友股份(603429.SH)公佈,截止2020年12月28日,控股股東徐善水累計通過大宗交易方式減持公司股份1514.29萬股,佔公司總股本的3.98%。股東楊二果累計通過上海證券交易所交易系統集中競價方式減持公司股份234.84萬股,佔公司總股本的0.61%;周少俊累計通過上海證券交易所交易系統集中競價方式減持公司股份84.03萬股,佔公司總股本的0.22%;孫志松累計通過上海證券交易所交易系統集中競價方式減持公司股份331.237萬股,佔公司總股本的0.87%。本次減持計劃提前終止,未完成減持的股份在減持計劃期間內將不再減持。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.